Albert G. Zamora

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

We identify top-notch #HealthTech projects to build market-driven startups. Matching Barcelona & San Francisco & San Sebastián we guide entrepreneurs beyond the acceleration.

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

ACCIÓ is the Catalan Government’s agency for business competitiveness. Belonging to the Ministry of Business and Labour, it is the public facing organisation working to contribute to the transformation of Catalan companies. It has a network of 40 offices worldwide, 7 regional offices in Catalonia, and collaborates with public and private institutions in building tomorrow’s company, today. ACCIÓ works so that enterprise can identify the changes in its environment, take advantage of them and transform, enhancing everything that can set it apart and enhance competitiveness. This differentiation occurs primarily through the key combination for business competitiveness: innovation + internationalization. We are driven by three main goals: to increase the productivity of Catalan companies, to accompany them in their transformation and global positioning challenges, and, finally, to strengthen the attractiveness of Catalonia as a destination for high-value foreign investment. These goals are designed to have a positive impact on economic growth and job creation.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.